Ampligen® is the trade name in the United States for rintatolimod.
Hemispherx Biopharma Receives the European Patent Office Grant of New Composition of Matter Patent Covering Ampligen(R) Formulations
Ampligen®, an experimental therapeutic, may be able to meet this requirement.
No assurances can be given that the EMA will approve Ampligen®/rintatolimod for treatment of EVD.
Hemispherx Announces First Shipment of Rintatolimod (Ampligen®) to Early Access Program in Europe
Hemispherx's flagship products include Alferon N Injection®, the experimental therapeutics Ampligen® and Alferon® LDO.
Hemispherx's flagship products include Alferon® N Injection® and the experimental therapeutics Ampligen® and Alferon® LDO.
Hemispherx’s flagship products include Alferon N Injection® and the experimental therapeutics Ampligen® and Alferon® LDO.
Hemispherx's flagship products include Alferon N Injection®, the experimental therapeutics Ampligen® and Alferon® LDO.
Hemispherx’s flagship products include Alferon N Injection® and the experimental therapeutics Ampligen® and Alferon® LDO.
Hemispherx's President, Thomas K. Equels, stated, "We are pleased to announce this significant step in our business plan for Ampligen.
In Argentina, rintatolimod (Ampligen) has just been commercially approved for the severe disabling form of ME/CFS.
Hemispherx's flagship products include Alferon N Injection® and the experimental therapeutics Ampligen® and Alferon® LDO.
Hemispherx's flagship products include Alferon N Injection® and the experimental therapeutics Ampligen® and Alferon® LDO.
In Argentina, rintatolimod (Ampligen) has just been commercially approved for the severe disabling form of ME/CFS.
Hemispherx's flagship products include Alferon N Injection®, the experimental therapeutics Ampligen® and Alferon® LDO.
Hemispherx's flagship products include Alferon N Injection®, the experimental therapeutics Ampligen® and Alferon® LDO.
Hemispherx's flagship products include Alferon N Injection®, the experimental therapeutics Ampligen® and Alferon® LDO.
Any failure to satisfy the FDA's requirements could significantly delay, or preclude outright, approval of the Ampligen NDA.
Ampligen is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system.
Requêtes fréquentes français :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Requêtes fréquentes anglais :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Traduction Translation Traducción Übersetzung Tradução Traduzione Traducere Vertaling Tłumaczenie Mετάφραση Oversættelse Översättning Käännös Aistriúchán Traduzzjoni Prevajanje Vertimas Tõlge Preklad Fordítás Tulkojumi Превод Překlad Prijevod 翻訳 번역 翻译 Перевод